Traumatic Brain Injury – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Traumatic Brain Injury – Pipeline Review, H1 2020’, provides an overview of the Traumatic Brain Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope


– The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury

– The report reviews pipeline therapeutics for Traumatic Brain Injury by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Traumatic Brain Injury therapeutics and enlists all their major and minor projects

– The report assesses Traumatic Brain Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Traumatic Brain Injury”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acelerox LLC

ALSP Inc

AlzeCure Pharma AB

AMAG Pharmaceuticals Inc

Amarantus Bioscience Holdings Inc

American CryoStem Corp

Anagin Inc

Anida Pharma Inc

Annovis Bio Inc

AntiRadical Therapeutics LLC

Anvyl LLC

Aptinyx Inc

Astrocyte Pharmaceuticals Inc

Athersys Inc

Avanir Pharmaceuticals Inc

Bessor Pharma LLC

Beyond Barriers Therapeutics Inc

Biogen Inc

BioIncept LLC

Bioquark Inc

Brain-Gen LLC

CalciMedica Inc

CavoGene LifeSciences

CellCure

Cellvation Inc

CereSpir Inc

Chimerix Inc

Chrysalis BioTherapeutics Inc

Cognosci Inc

Complement Pharma BV

Deha Pharmaceutical LLC

Eagle Pharmaceuticals Inc

Eisai Co Ltd

Epigen Biosciences Inc

Fortuna Fix Inc

GABA Therapeutics Inc

GNT Pharma Co Ltd

Hemarina SA

Hibernaid Inc

Hillhurst Biopharmaceuticals Inc

Hope Biosciences LLC

Hoverink Biotechnologies Inc

ImmunoChem Therapeutics LLC

Impression Healthcare Ltd

Inflammatory Response Research Inc

International Stem Cell Corp

Ischemix Inc

JT Pharmaceuticals Inc

Kalytera Therapeutics Inc

KannaLife Sciences Inc

LA Cell Inc

Levolta Pharmaceuticals Inc

Mapreg SAS

Mercaptor Discoveries Inc

MetVital Inc

NeuExcell Therapeutics Inc

NeurAegis Inc

Neuren Pharmaceuticals Ltd

NeurExo Sciences LLC

Neurodon LLC

Neuronasal LLC

NeuroNascent Inc

NeuroTrauma Sciences LLC

Neurotrope Bioscience Inc

NeuroVive Pharmaceutical AB

New World Laboratories Inc

NoNO Inc

NuvOx Pharma LLC

Nyrada Inc

OncoSynergy Inc

Orpheris Inc

Oxeia Biopharmaceuticals Inc

Peptron Inc

PharmatrophiX Inc

Praetego Inc

Prevacus Inc

ProNeurogen Inc

ProThera Biologics Inc

Protheragen Inc

Qrons Inc

Radikal Therapeutics Inc

RegeneRx Biopharmaceuticals Inc

Resolys Bio Inc

RHNanopharmacuticals LLC

Rubicon Biotechnology Inc

SanBio Inc

Seneca Biopharma Inc

Shinkei Therapeutics LLC

Silver Creek Pharmaceuticals Inc

Spinogenix Inc

STATegics Inc

Stemedica Cell Technologies Inc

Swedish Orphan Biovitrum AB

Tellus Therapeutics Inc

Tetra Therapeutics

Thera Neuropharma Inc

Therapeutic Solutions International Inc

Therapix Biosciences Ltd

Theratome Bio Inc

TikoMed AB

Tiziana Life Sciences Plc

Tria Bioscience Corp

vasopharm GmbH

VG Life Sciences Inc

Virogenomics BioDevelopment Inc

Xcelthera INC

Xonovo Inc

ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Traumatic Brain Injury Overview

Traumatic Brain Injury Therapeutics Development

Traumatic Brain Injury Therapeutics Assessment

Traumatic Brain Injury Companies Involved in Therapeutics Development

Traumatic Brain Injury Drug Profiles

Traumatic Brain Injury Dormant Projects

Traumatic Brain Injury Discontinued Products

Traumatic Brain Injury Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Traumatic Brain Injury, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Traumatic Brain Injury – Pipeline by Acelerox LLC, H1 2020

Traumatic Brain Injury – Pipeline by ALSP Inc, H1 2020

Traumatic Brain Injury – Pipeline by AlzeCure Pharma AB, H1 2020

Traumatic Brain Injury – Pipeline by AMAG Pharmaceuticals Inc, H1 2020

Traumatic Brain Injury – Pipeline by Amarantus Bioscience Holdings Inc, H1 2020

Traumatic Brain Injury – Pipeline by American CryoStem Corp, H1 2020

Traumatic Brain Injury – Pipeline by Anagin Inc, H1 2020

Traumatic Brain Injury – Pipeline by Anida Pharma Inc, H1 2020

Traumatic Brain Injury – Pipeline by Annovis Bio Inc, H1 2020

Traumatic Brain Injury – Dormant Projects, H1 2020

Traumatic Brain Injury – Dormant Projects, H1 2020 (Contd..1), H1 2020

Traumatic Brain Injury – Dormant Projects, H1 2020 (Contd..2), H1 2020

Traumatic Brain Injury – Dormant Projects, H1 2020 (Contd..3), H1 2020

Traumatic Brain Injury – Dormant Projects, H1 2020 (Contd..4), H1 2020

Traumatic Brain Injury – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Traumatic Brain Injury, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports